Vivace Therapeutics reported preclinical efficacy for VT‑3989, a TEAD inhibitor showing activity in NF2‑deficient meningioma models and other aggressive tumor types. Company data presented include in vitro and in vivo models where TEAD pathway blockade reduced tumor growth, supporting VT‑3989’s progression into early clinical testing for advanced solid tumors. TEAD inhibitors target YAP/TAZ‑driven transcription downstream of the Hippo pathway, an axis implicated in tumor proliferation and therapy resistance. Vivace’s disclosure positions VT‑3989 among a growing class of developmental TEAD inhibitors and will prompt interest in dosing strategy, biomarker selection and combination opportunities in clinical trials.